Modifications in Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters After α-Particle-Emitting 227Th-trastuzumab Therapy of HER2-Expressing Ovarian Cancer Xenografts-Reference-Cited by-同舟云学术

Modifications in Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters After α-Particle-Emitting 227Th-trastuzumab Therapy of HER2-Expressing Ovarian Cancer Xenografts

Published:2013-09 Issue:1 Volume:87 Page:153-159
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Heyerdahl Helen,Røe Kathrine,Brevik Ellen Mengshoel,Dahle Jostein

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference20 articles.

1. An overview of targeted alpha therapy;Kim;Tumour Biol,2012

2. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate;Dahle;Blood,2007

3. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts;Abbas;Nucl Med Commun,2012

4. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab;Heyerdahl;PLoS ONE,2012

5. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation;Dahle;Int J Radiat Oncol Biol Phys,2008

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Alpha Therapy with Thorium-227;Cancer Biotherapy and Radiopharmaceuticals;2020-08-01

2. Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models;Contrast Media & Molecular Imaging;2019-09-22

3. Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer;Neoplasia;2019-01

4. Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer;Mathematical Medicine and Biology: A Journal of the IMA;2018-09-19

5. Combination of177Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma;European Journal of Haematology;2018-08-31